The global Cell and Gene Therapy Market is expected to reach USD 6,570.0 Million by 2027, according to a new report by Emergen Research.
The global Cell and Gene Therapy Market is expected to reach USD 6,570.0 Million by 2027, according to a new report by Emergen Research. Major factors expected to drive the growth of the market include the development of more effective cell and gene therapies, the increasing investments in cell and gene therapy research, the strong government support for this therapy, and the rising incidence of cancer and other chronic diseases. Also, the launch of CAR T-cell immunotherapy for the treatment of different types of cancer is boosting the market growth. However, the stringent regulations related to cell and gene therapy are restraining the growth of this market to some extent.
Cell therapy is an emerging area of regenerative medicine that uses cells as therapeutic agents to treat various diseases, including cancer, genetic disorders, and degenerative diseases. In cell therapy, living cells are introduced into the patient’s body to replace or repair damaged cells. Cell therapy can be used to treat diseases such as cancer, heart disease, and diabetes.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/27
Gene therapy is a type of cell therapy that uses genes to treat or prevent disease. In gene therapy, genes are introduced into the patient’s cells to replace or repair damaged genes. Gene therapy can be used to treat diseases such as cancer, genetic disorders, and degenerative diseases.
The sanction of cell and gene therapy focused on early chimeric antigen receptor T-cell immunotherapy has provided a huge push to the cell and gene therapy industry development. In August 2017, the U.S. FDA approved tisagenlecleucel (Kymriah), a CD19-targeted CAR T-cell immunotherapy developed by Novartis for the treatment of certain relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) patients up to 25 years of age. Furthermore, in October 2017, the U.S. FDA approved axicabtagene ciloleucel (Yescarta), a CD19-targeted CAR T-cell immunotherapy developed by Kite Pharma for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Some Key Highlights from the Report
- By indication, large b-cell lymphoma contributed to a larger market share in 2019 owing to the FDA approvals of CAR T-cell therapies tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), for the treatment of relapsed or refractory large B-cell lymphoma. In addition, in September 2019, the FDA approved brexucabtagene autoleucel (Tecartus), a CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior therapies.
- By vector type, retrovirus and gammaretrovirus dominated the market during forecast period owing to the ability of these viruses to infect both dividing and nondividing cells. This in turn, results in large-scale production of recombinant protein. However, adenovirus is anticipated to grow at the highest CAGR during the forecast period due to its feature of high-efficiency gene transfer and lack of pathogenicity.
- The oncology segment accounted for the largest share of the global cell and gene therapy market in 2019. The high growth of this segment can be attributed to the rising government initiatives and funding for cancer research and increasing number of clinical trials for cell and gene therapies.
- North America held the largest share of the market in 2019 owing to the increasing prevalence of cancer and other chronic diseases, availability of funds for research and development, and the presence of key market players.
- Asia-Pacific is expected to grow at the highest CAGR during the forecast period due to government initiatives to promote cell and gene therapy-based research and development activities, rising disposable incomes, and increasing healthcare expenditure.
- Spark Therapeutics LLC, Novartis AG, Gilead Sciences Inc., Bluebird Bio, GlaxoSmithKline, Celgene Corporation, Shire PLC, Sangamo Biosciences, Voyager Therapeutics, and Dimension Therapeutics are just a few of the important participants.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/cell-and-gene-therapy-market
Emergen Research has segmented the global Cell and Gene Therapy Market on the basis of indication, vector type, and region:
Indication Outlook (Revenue, USD Billion; 2017-2027)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-Cell Lymphoma
- ADA-SCID
- Others
Vector Outlook (Revenue, USD Billion; 2017-2027)
- Lentivirus
- AAV
- Retrovirus & Gammaretrovirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-Viral Plasmid Vector
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- US.
- Canada
- Europe
- Germany
- UK
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- MEA
- Saudi Arabia
- UAE
- Rest of MEA
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/27
Explore More Reports Emergen Research:
Blockchain Supply Chain Market
Carbon Neutral Data Center Market
Non-Volatile Memory Express Market
Green Technology and Sustainability Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-cell-and-gene-therapy-market